Apples and oranges? Can second generation vaccines become as low cost as generic medicines?-Reference-Cited by-同舟云学术

Apples and oranges? Can second generation vaccines become as low cost as generic medicines?

Published:2019-05 Issue:22 Volume:37 Page:2910-2914
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Nguyen Aurelia,Schwalbe Nina^ORCID

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference25 articles.

1. Sustainable Development Goals Report 2016. UN; 2016.

2. Assembling a global vaccine development pipeline for infectious diseases in the developing world;Serdobova;Am J Public Health,2006

3. Developing biological standards for vaccine evaluation;Page;Future Virol,2017

4. 2017-Bio-Standards-WOrking-Group-Summary-1.pdf [Internet]. [cited 2019 Feb 16]. Available from: https://cepi.net/wp-content/uploads/2019/01/2017-Bio-Standards-WOrking-Group-Summary-1.pdf.

5. Gerdts V, Wilson HL, Meurens F, van Drunen Littel - van den Hurk S, Wilson D, Walker S, et al. Large Animal Models for Vaccine Development and Testing. ILAR J. 2015 May 19;56(1):pp. 53–62.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Active Immunotherapy for the Prevention of Alzheimer’s and Parkinson’s Disease;Vaccines;2024-08-28

2. Bold moves for vaccine manufacturing equity;The Lancet;2023-09

3. Sustainable vaccine manufacturing in low- and middle-Income countries;Vaccine;2022-11

4. Compulsory licensing: an effective tool for securing access to Covid-19 vaccines for developing states?;Legal Studies;2022-08-05

5. Biotechnologies to Bridge the Schism in the Bioeconomy;Energies;2021-12-13